Too little menstrual flow, beware of breast cancer

Too little menstrual flow, beware of breast cancer

1. The incidence of breast cancer is closely related to the level of estrogen in the body. Women who are worried about themselves should look at the "high-risk factors" for breast cancer. How many of them are there: menarche at the age of less than 12 or menopause at the age of more than 55; the birth age of the first child is over 35, or never born or breastfeeding after childbirth; obesity, weight gain or estrogen replacement therapy after menopause. Studies have shown that the above people have a 3-3 times higher risk of breast cancer than ordinary people. The occurrence of breast cancer is also related to endocrine disorders in the human body. Women with short menstrual cycles and less menstrual blood should also pay attention to this, which may be caused by low estrogen levels, indicating that the estrogen secretion in the body has not reached a balanced and stable state.

2. The latest research found that some breast cancers are "hereditary" with high risk, such as those with BRCA-1 mutation gene, who have a lifetime chance of developing breast cancer of more than 80%; and the disease is early, and women are more likely to suffer from ovarian cancer at the same time. If the mother has unilateral breast cancer, the child's chance of developing breast cancer is twice that of ordinary people; if the mother has premenopausal and bilateral malignant tumors, the child's chance of developing breast cancer will be seven or eight times higher.

3. Women should ask a breast cancer specialist to assess whether they are at high risk. People over 40 should have a mammogram every year. If breast abnormalities are found, they should see a doctor as soon as possible. In terms of treatment methods, most people still need adjuvant chemotherapy to reduce the risk of tumor recurrence. At this year's European Breast Cancer Conference, the application of the TAC regimen of chemotherapy, taxotere, hydroxydinocycline, and cyclophosphamide, significantly improved the survival rate and overall survival rate of disease-free patients.